Table 1. Patient characteristics.
| Characteristic | Optimized group (N=60) | Standard group (N=154) | P value |
|---|---|---|---|
| Sex | 0.64 | ||
| Male | 39 (65.0%) | 107 (69.5%) | |
| Female | 21 (35.0%) | 47 (30.5%) | |
| Age (years) | 0.49 | ||
| <50 | 28 (46.7%) | 80 (51.9%) | |
| ≥50 | 32 (53.3%) | 74 (48.1%) | |
| Clinical stage | 0.20 | ||
| II–III | 38 (63.3%) | 81 (52.6%) | |
| IVA | 22 (36.7%) | 73 (47.4%) | |
| T classification | 0.52 | ||
| T1–2 | 22 (36.7%) | 48 (31.2%) | |
| T3–4 | 38 (63.3%) | 106 (68.8%) | |
| N classification | 0.16 | ||
| N1 | 38 (63.3%) | 81 (52.6%) | |
| N2 | 17 (28.3%) | 45 (29.2%) | |
| N3 | 5 (8.3%) | 28 (18.2%) | |
| Induction chemotherapy cycles | 0.52 | ||
| 2 | 53 (88.3%) | 130 (84.4%) | |
| 3 | 7 (11.7%) | 24 (15.6%) | |
| Induction chemotherapy regimen | 0.88 | ||
| TP | 34 (56.7%) | 84 (54.5%) | |
| TPF | 26 (43.3%) | 70 (45.5%) | |
| Adjuvant chemotherapy | 0.08 | ||
| Yes | 56 (93.3%) | 128 (83.1%) | |
| No | 4 (6.7%) | 26 (16.9%) | |
| Targeted therapy | 0.73 | ||
| Yes | 43 (71.7%) | 115 (74.7%) | |
| No | 17 (28.3%) | 39 (25.3%) | |
TP, docetaxel + cisplatin; TPF, docetaxel + cisplatin + fluorouracil.